• Molecular NameDacarbazine
  • SynonymBiocarbazine R; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; DIC; DTIC; Dtic-Dome; DTIE; ICDMT; ICDT; Imidazole Carboxamide
  • Weight182.187
  • Drugbank_IDDB00851
  • ACS_NO4342-03-4
  • Show 3D model
  • LogP (experiment)-0.25
  • LogP (predicted, AB/LogP v2.0)-0.75
  • pka7.03
  • LogD (pH=7, predicted)-1.62
  • Solubility (experiment)4.22 mg/ml
  • LogS (predicted, ACD/Labs)(ph=7)-0.03
  • LogSw (predicted, AB/LogsW2.0)20.14
  • Sw (mg/ml) (predicted, ACD/Labs)171.31
  • No.of HBond Donors3
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds3
  • TPSA95.44
  • StatusFDA approved
  • AdministrationIV
  • PharmacologyAn antineoplastic chemotherapy drug used in the treatment of various cancers, among them malignant melanoma, Hodgkin lymphoma, sarcoma, and islet cell carcinoma of the pancreas.
  • Absorption_valueN/A
  • Absorption (description)Erratic, slow and incomplete
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding5.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmN/A
  • Half life5 h
  • Excretion40% renal (unchanged)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)LD50=350mg/kg